Last reviewed · How we verify
Corticosteroids alone
Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune conditions (specific indication in phase 3 trial not specified).
At a glance
| Generic name | Corticosteroids alone |
|---|---|
| Also known as | Solupred, Disperlone, Methabiogen, Epicopred |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Corticosteroids are synthetic derivatives of cortisol that work by entering cells and binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and proliferation. The result is broad anti-inflammatory and immunosuppressive effects across multiple organ systems.
Approved indications
- Inflammatory and autoimmune conditions (specific indication in phase 3 trial not specified)
Common side effects
- Hyperglycemia
- Hypertension
- Osteoporosis
- Immunosuppression/increased infection risk
- Cushingoid features
- Mood disturbances
Key clinical trials
- Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. (PHASE3)
- OMT for Adhesive Capsulitis (PHASE4)
- Tocilizumab in Lung Transplantation (PHASE2)
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome (PHASE1, PHASE2)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corticosteroids alone CI brief — competitive landscape report
- Corticosteroids alone updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI